Head-To-Head Review: Immunovant (NASDAQ:IMVT) vs. Northwest Biotherapeutics (OTCMKTS:NWBO)

Northwest Biotherapeutics (OTCMKTS:NWBO) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Volatility and Risk

Northwest Biotherapeutics has a beta of -0.86, meaning that its share price is 186% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

Earnings and Valuation

This table compares Northwest Biotherapeutics and Immunovant”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Northwest Biotherapeutics	$1.38 million	342.75	-$83.78 million	($18.26)	-0.02
Immunovant	N/A	N/A	-$413.84 million	($2.84)	-9.25

Northwest Biotherapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Northwest Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Northwest Biotherapeutics and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Northwest Biotherapeutics	-9,580.90%	N/A	-313.92%
Immunovant	N/A	-81.55%	-73.09%

Institutional & Insider Ownership

0.0% of Northwest Biotherapeutics shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 2.4% of Northwest Biotherapeutics shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Northwest Biotherapeutics and Immunovant, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Northwest Biotherapeutics	0	0	0	0	0.00
Immunovant	1	3	6	1	2.64

Immunovant has a consensus target price of $30.78, indicating a potential upside of 17.16%. Given Immunovant’s stronger consensus rating and higher probable upside, analysts plainly believe Immunovant is more favorable than Northwest Biotherapeutics.

Summary

Immunovant beats Northwest Biotherapeutics on 9 of the 14 factors compared between the two stocks.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.